A Historical View on the Creation of the European Society for Cell and Gene Therapy

2013 ◽  
Vol 24 (1) ◽  
pp. 4-11 ◽  
Author(s):  
Odile Cohen-Haguenauer
Keyword(s):  
Gene Therapy ◽  
European Society ◽  
Historical View ◽  
The Creation ◽  
Cell And Gene Therapy

scholarly journals Accelerating Innovation in the Creation of Biovalue

2017 ◽  
Vol 42 (5) ◽  
pp. 925-946 ◽  
Author(s):  
John Gardner ◽  
Andrew Webster
Keyword(s):  
Gene Therapy ◽  
Regenerative Medicine ◽  
Cell Therapy ◽  
Sociotechnical Imaginaries ◽  
The Creation ◽  
Cell And Gene Therapy

The field of regenerative medicine (RM) has considerable therapeutic promise that is proving difficult to realize. As a result, governments have supported the establishment of intermediary agencies to “accelerate” innovation. This article examines in detail one such agency, the United Kingdom’s Cell and Gene Therapy Catapult (CGTC). We describe CGTC’s role as an accelerator agency and its value narrative, which combines both “health and wealth.” Drawing on the notion of sociotechnical imaginaries, we unpack the tensions within this narrative and its instantiation as the CGTC cell therapy infrastructure is built and engages with other agencies, some of which have different priorities and roles to play within the RM field.

Attenuating Muscle Wasting: Cell and Gene Therapy Approaches

2003 ◽  
Vol 4 (7) ◽  
pp. 575-585 ◽  
Author(s):  
A. Musaro ◽  
N. Rosenthal
Keyword(s):  
Gene Therapy ◽  
Muscle Wasting ◽  
Cell And Gene Therapy

Fetal stem cell and gene therapy

2017 ◽  
Vol 22 (6) ◽  
pp. 410-414 ◽  
Author(s):  
Russell Witt ◽  
Tippi C. MacKenzie ◽  
William H. Peranteau
Keyword(s):  
Gene Therapy ◽  
Stem Cell ◽  
Fetal Stem Cell ◽  
Cell And Gene Therapy

How institutional biosafety committees contribute to safety, capacity and regulatory approvals in cell and gene therapy trials

Cytotherapy ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. S206
Author(s):  
G. O’Sullivan ◽  
B. Yu ◽  
C. Bailey ◽  
Z. Velickovic ◽  
J. Rasko
Keyword(s):  
Gene Therapy ◽  
Cell And Gene Therapy

Retinal Transplantation, Stem Cell and Gene Therapy in Retinitis Pigmentosa

2021 ◽  
pp. 131-139
Keyword(s):  
Gene Therapy ◽  
Stem Cell ◽  
Retinitis Pigmentosa ◽  
Retinal Dystrophy ◽  
Gene Replacement ◽  
Disease Genes ◽  
Functional Roles ◽  
Tunnel Vision ◽  
Hereditary Retinal Dystrophy ◽  
Cell And Gene Therapy

Retinitis pigmentosa is the most common hereditary retinal dystrophy which has marked clinical and genetic heterogeneity. Common presentations among this disorder include night blindness, tunnel vision, and subsequent progression to complete blindness respectively. The known causative disease genes have a variety of developmental and functional roles, with mutations in more than 120 genes shown to be responsible for the phenotypes. In addition, mutations within the same gene have been shown to cause different disease phenotypes, even within the same family, highlighting further levels of complexity. In recent years significant advancements have been made in the understanding of the pathogenesis of the disease and stem cell and gene replacement treatments have been proposed as potentially efficacious therapies. This review summarizes the clinical development of retinal stem cell and gene therapy.

Sign in / Sign up

Export Citation Format

Share Document